膜杰作
Star Staining
描述（Description）
The Human IL-4 R alpha/IL-13 R alpha 1 (Luc) HEK293 Reporter Cell with endogenous IL-4 R alpha and IL-13 R alpha 1 expression was engineered to express STAT6 signaling response element. When stimulated with human IL-4 or IL-13 protein, receptor-mediated signaling can drive STAT6-mediated luminescence. Neutralization of biological effect of human IL-4 and IL-13 protein by corresponding antibody results in a decrease in luminescence.
应用说明（Application）
• Screen for neutralizing antibodies blocking the stimulation of human IL-4 and IL-13 protein.
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Puromycin (2 μg/mL)
培养基（Culture Medium）
DMEM medium + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
Application
Inhibition of human IL-4 protein-induced reporter activity by anti-human IL-4 R alpha neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human IL-4 protein (Cat.No.IL4-H4218) with a final concentration of 0.002 μg/mL. The EC50 of anti-human IL-4 R alpha neutralizing antibody is approximately 0.0054 μg/mL.
Protocol
Inhibition of human IL-13 protein-induced reporter activity by anti-human IL-4 R alpha neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human IL-13 protein (Cat.No.IL3-H52H4) with a final concentration of 0.1 μg/mL. The EC50 of anti-human IL-4 R alpha neutralizing antibody is approximately 0.0023 μg/mL.
Protocol
Signaling Bioassay
Response to human IL-4 protein (RLU).
The Human IL-4 R alpha/IL-13 R alpha 1 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-4 protein (Cat.No.IL4-H4218). The EC50 was approximately 0.00059 μg/mL.
Protocol
Response to human IL-4 protein (FOLD).
The Human IL-4 R alpha/IL-13 R alpha 1 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-4 protein (Cat.No.IL4-H4218). The max induction fold was approximately 33.
Protocol
Response to human IL-13 protein (RLU).
The Human IL-4 R alpha/IL-13 R alpha 1 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-13 protein (Cat.No.IL3-H52H4). The EC50 was approximately 0.14 μg/mL.
Protocol
Response to human IL-13 protein (FOLD).
The Human IL-4 R alpha/IL-13 R alpha 1 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-13 protein (Cat.No.IL3-H52H4). The max induction fold was approximately 30.
Protocol
Passage Stability
Passage stability analysis by Signaling Bioassay.
The continuously growing Human IL-4 R alpha/IL-13 R alpha 1 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-13 protein. Human IL-13 protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 4-22.
Protocol
如有相关细胞池需求请联系我们
背景（Background）
Interleukin-4 is a key cytokine associated with allergy and asthma. In the presence of IL-4 and IL-13, cytokines that are produced in a Th-2 type response, particularly during allergy and parasitic infections, macrophages become differentially activated, And this cytokine is a ligand for interleukin 4 receptor. The interleukin 4 receptor also binds to IL13, which may contribute to many overlapping functions of this cytokine and IL13. STAT6, a signal transducer and activator of transcription, has been shown to play a central role in mediating the immune regulatory signal of this cytokine. Recently, researcher found that the cytokine IL-4 plays a key role in development of innate CD8+ T cells in the thymus of several gene-deficient mouse strains, including Itk, KLF2, CBP and Id3, without previous exposure to antigen.
License Disclosure
This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
